Artisan Partners Limited Partnership Sells 28,849 Shares of Humana Inc. $HUM

Artisan Partners Limited Partnership lessened its holdings in shares of Humana Inc. (NYSE:HUM) by 3.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 702,637 shares of the insurance provider’s stock after selling 28,849 shares during the period. Artisan Partners Limited Partnership owned 0.58% of Humana worth $182,805,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Revolve Wealth Partners LLC bought a new stake in shares of Humana in the 4th quarter valued at about $202,000. Woodline Partners LP lifted its stake in shares of Humana by 460.0% in the first quarter. Woodline Partners LP now owns 10,192 shares of the insurance provider’s stock worth $2,697,000 after acquiring an additional 8,372 shares during the period. Sivia Capital Partners LLC lifted its stake in shares of Humana by 53.7% in the second quarter. Sivia Capital Partners LLC now owns 1,293 shares of the insurance provider’s stock worth $316,000 after acquiring an additional 452 shares during the period. Bessemer Group Inc. boosted its holdings in Humana by 11.2% in the second quarter. Bessemer Group Inc. now owns 1,983 shares of the insurance provider’s stock valued at $485,000 after acquiring an additional 199 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Humana during the 2nd quarter valued at approximately $1,523,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on HUM. Raymond James Financial dropped their price target on shares of Humana from $340.00 to $230.00 and set an “outperform” rating on the stock in a research report on Friday, February 13th. Weiss Ratings restated a “sell (d+)” rating on shares of Humana in a report on Thursday, January 22nd. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $344.00 price target on shares of Humana in a research report on Tuesday, January 6th. Guggenheim lowered their price objective on Humana from $312.00 to $252.00 and set a “buy” rating for the company in a research report on Thursday, February 12th. Finally, Cantor Fitzgerald cut their target price on Humana from $290.00 to $201.00 and set a “neutral” rating on the stock in a research report on Thursday, February 12th. Seven equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $225.48.

Humana Price Performance

HUM stock opened at $186.88 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.00 and a current ratio of 2.00. The business has a 50-day simple moving average of $230.72 and a two-hundred day simple moving average of $256.54. The company has a market capitalization of $22.54 billion, a P/E ratio of 19.03, a price-to-earnings-growth ratio of 1.88 and a beta of 0.44. Humana Inc. has a 52-week low of $169.61 and a 52-week high of $315.35.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.01) by $0.05. The company had revenue of $32.64 billion for the quarter, compared to analyst estimates of $32.08 billion. Humana had a return on equity of 11.43% and a net margin of 0.92%.The company’s revenue for the quarter was up 11.3% on a year-over-year basis. During the same quarter last year, the company earned ($2.16) earnings per share. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. Research analysts expect that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 24th. Shareholders of record on Friday, March 27th will be issued a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date of this dividend is Friday, March 27th. Humana’s payout ratio is currently 36.05%.

Humana News Roundup

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Insider buying: Humana insider Sanjay Shetty purchased 810 shares at about $185.21, increasing his stake ~7.5% — a classic signal of insider confidence that can support near‑term sentiment. Insider Buying
• Positive Sentiment: CenterWell expansion: Humana’s CenterWell acquired a Florida primary-care network, expanding its direct-care footprint and supporting longer‑term membership and care‑coordination strategies that investors reward. Acquisition Article
• Positive Sentiment: Dividend + institutional inflows: The company declared a quarterly dividend (annualized ~$3.54, ~2.0% yield) and filings show large institutional buying from groups like Capital International, MFS and Norges Bank — both items support demand for the stock. MarketBeat Humana
• Neutral Sentiment: Investor presentation scheduled: CEO Jim Rechtin and CFO Celeste Mellet will present at the Leerink Partners Global Healthcare Conference on March 10; management commentary could move the shares depending on tone and new disclosures. Conference Notice
• Neutral Sentiment: Local operations/profile piece: A regional profile on Humana Group Benefits in San Antonio highlights relationship-driven growth but is unlikely to move the stock materially. Local Profile
• Negative Sentiment: Analyst downgrades and cuts: Barclays cut its price target to $176 and kept an equal‑weight rating; other shops (Zacks, Leerink, Weiss) have issued cautious or negative notes — analyst tone is pressuring sentiment and caps upside. Barclays PT Cut
• Negative Sentiment: Zacks / peer comparison: Zacks’ commentary and comparative pieces argue UnitedHealth (UNH) has better upside given scale versus Humana, and Zacks moved to a more bearish stance — a headwind for investors seeking sector winners. Zacks Comparison

Insider Activity

In other news, insider Sanjay K. Shetty purchased 810 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The shares were acquired at an average cost of $185.21 per share, for a total transaction of $150,020.10. Following the completion of the acquisition, the insider owned 11,657 shares in the company, valued at $2,158,992.97. This trade represents a 7.47% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.37% of the stock is currently owned by insiders.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.